沪深两市全天主力资金净流出239.32亿元，其中，科创板主力资金净流出18.45亿元，主力资金净流入的 有244只股，主力资金净流出的有342只股。 上市5日内的资金净流出较多的是C汉邦，今日主力资金净流出2755.93万。 证券时报·数据宝统计显示，今日科创板个股上涨的有157只，涨停的有三生国健等1只，下跌的有422 只。其中，上市5日内的有C汉邦等，今日跌幅较高的有C汉邦，跌幅为4.82%。 从主力资金连续性进行观察，共有59只个股主力资金连续3个交易日以上持续净流入，连续净流入天数 最多的是华大智造、特宝生物等2只股，主力资金均连续净流入10天。主力资金连续流出的个股有102 只，连续流出天数最多的是先锋精科，该股已连续25个交易日净流出；连续净流出天数较多的还有三达 膜、上海合晶等，主力资金分别连续流出15天、13天。（数据宝） 资金流向方面，今日主力资金净流入的科创板股共有244只，其中，5只个股主力资金净流入超5000万 元，天岳先进主力资金净流入7659.22万元，净流入资金居首；九号公司、容百科技紧随其后，全天净 流入资金分别为6527.97万元、5470.12万元。主力资金净流出的有342 ...

（文章来源：证券时报网） 佳合科技 | 301501 | 恒鑫生活 | 78.88 | 35.12 | -6.79 | | --- | --- | --- | --- | --- | | 603014 | C威高 | 37.11 | 34.65 | -4.53 | | 688755 | C汉邦 | 46.83 | 34.54 | -4.82 | | 920068 | 天工股份 | 20.90 | 33.73 | -7.11 | | 870299 | 灿能电力 | 23.78 | 33.65 | -5.63 | | 001206 | 依依股份 | 24.35 | 33.46 | 6.15 | | 300040 | 九洲集团 | 8.10 | 33.26 | -4.48 | | 301488 | 豪恩汽电 | 76.00 | 32.75 | -2.25 | | 600610 | 中毅达 | 15.79 | 32.63 | -5.11 | | 300703 | 创源股份 | 18.58 | 32.49 | -2.31 | | 837023 | 芭薇股份 | 29.28 | 32.19 | -4.38 | | 301 ...

科创50指数今日上涨0.24%，报收997.68点，科创板全日成交量22.28亿股，成交额728.96亿元，加权平 均换手率为1.32%。 证券时报·数据宝统计显示，今日可交易科创板股中，407只股收盘上涨，涨幅超过10%的有7只，涨幅 在5%至10%的有24只，收盘下跌的有175只。 科创板股换手率区间分布显示，换手率超过20%的有3只，换手率10%~20%的有4只，换手率5%~10%的 34只，换手率3%~5%的62只，换手率1%~3%的309只，换手率不足1%的有175只。 换手率最高的是C汉邦，该股为上市5日内的新股，收盘涨幅5.69%，换手率50.32%，日成交额3.89亿 元，全天主力资金净流入1365.88万元。其次是航天南湖，该股今日收盘下跌6.42%，全天换手率 29.39%，成交额8.53亿元，换手率居前的还有利扬芯片、中邮科技、春立医疗等，换手率分别为 22.58%、18.99%、13.61%。 统计显示，换手率超5%的高换手率个股中，C汉邦为上市5日内的新股。 市场表现看，换手率超5%的个股中，今日上涨的有30只，涨幅居前的有荣昌生物、益方生物、利扬芯 片等，分别上涨16.09%、15 ...

Core Viewpoint - C Hanbang (688755) experienced a significant increase of 102.46% on its first trading day, with a turnover rate of 75.65% and a transaction volume of 609 million yuan [2]. Group 1: Company Overview - C Hanbang is a high-tech enterprise focused on chromatography technology, integrating research and development, production, and sales. The company primarily provides professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [2]. Group 2: Market Performance - On its debut, C Hanbang's financing buy-in amounted to 49.50 million yuan, accounting for 8.13% of the total trading volume. The latest financing balance stands at 41.76 million yuan, representing 5.48% of the circulating market value [2]. - The stock attracted a net inflow of 210 million yuan from major funds on its first day, with large orders contributing a net inflow of 81.52 million yuan and big orders contributing 129 million yuan [2].

5月16日，在上海证券交易所，伴随着喜庆的开市锣声敲响，江苏汉邦科技股份有限公司成功登陆科创板。作为2025年科创板首家过会的IPO企业，汉邦 科技成为淮安第一家科创板上市公司。 摄影：谭鑫 通讯员：朱海涛 梁锦州 融媒体图片编辑：程钢 张大兵表示，汉邦科技将以此次上市为契机，持续加大研发投入，不断优化产品结构，积极拓展国内外市场渠道，坚定不移地朝着成为全球领先的色谱纯 化解决方案提供商的目标迈进，为中国乃至全球的制药、化工、食品天然产物、医美、新材料等领域贡献更多力量。 汉邦科技公司是淮安一家土生土长的民营企业，经过27年的稳步发展，在液相色谱这一领域深耕细作、勇攀高峰，逐步成长为行业标杆企业。 融媒体记者：唐筱葳 市长顾坤，中信证券股份有限公司高管、全球投资银行管理委员会主任孙毅，汉邦科技公司董事长、总经理张大兵致辞；上海证券交易所数字化专业委员 会副主任兼技术公司董事长张晓京与企业签订《科创板证券上市协议》。省委金融办副主任聂振平，市委常委、常务副市长林小明，市政府秘书长马乃 骏，淮安经开区党工委书记刘爱国共同见证。 顾坤向汉邦科技科创板上市表示祝贺。他说，汉邦科技成功登陆科创板，不仅是企业发展历程中的 ...

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 46.10 yuan, representing a 102.46% increase on the first day of trading [1] Company Overview - Hanbang Technology focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, and technical solutions [1] - The company is controlled by Zhang Dabin, who holds 23.75% of the shares directly and has a total control of 28.94% post-IPO [1] IPO Details - The company issued 22,000,000 shares at a price of 22.77 yuan per share, raising a total of 500.94 million yuan, with a net amount of 430.67 million yuan after deducting issuance costs [4] - The total issuance costs amounted to 70.27 million yuan, with underwriting fees of 37.29 million yuan [6] Financial Performance - For the years 2022 to 2024, the company reported revenues of 481.79 million yuan, 619.01 million yuan, and 690.88 million yuan, respectively, with net profits of 38.56 million yuan, 51.50 million yuan, and 79.34 million yuan [6][7] - In the first quarter of 2025, the company achieved total revenue of 165.23 million yuan, a year-on-year increase of 19.88%, and a net profit of 11.10 million yuan, up 93.79% from the previous year [9][10] Project Funding Allocation - The raised funds will be allocated to three main projects: 1. Annual production of 1,000 units of liquid chromatography separation equipment (19.30 million yuan) 2. Construction of a chromatography separation equipment R&D center (27.11 million yuan) 3. Annual production of 2,000 units of laboratory chromatography separation and purification instruments (22.48 million yuan) [5]

Group 1 - The Sci-Tech 50 Index opened slightly lower on May 16, closing at 995.24 points with a decline of 0.57% and a total trading volume of approximately 17.2 billion [1] - The Sci-Tech Comprehensive Index also opened lower but rose during the day, ultimately closing at 1170.20 points with an increase of 0.12% and a total trading volume of about 71.4 billion [1] - A significant number of stocks on the Sci-Tech Board reached new highs, with 16 stocks hitting their highest levels since 2025, and 36 stocks achieving new highs over the past 30 trading days [1] Group 2 - Hanbang Technology was listed on the Sci-Tech Board on May 16 with a stock code of 688755, and its share price increased by 102.46% on the first day, with a trading volume of approximately 609 million [2] - Excluding Hanbang Technology's first-day performance, the average increase for the remaining 586 stocks on the Sci-Tech Board was 0.70%, with an average turnover rate of 1.97% and a total trading volume of 708.34 billion [2] - In terms of individual stock performance, Hanjing Bio saw the highest increase at 12.09%, while Jingyuan Environmental experienced the largest decline at 9.38% [2] Group 3 - In terms of trading volume, Hanbang Technology led with 2.403 billion, while Conglin Technology had the lowest trading volume at 702.32 million [3] - The turnover rate for Aerospace Nanhu was the highest at 26.68%, while Longteng Optoelectronics had the lowest turnover rate at 0.09% [3]

就在刚刚 淮安再添一家上市公司 5月16日上午 江苏汉邦科技股份有限公司 在上海证券交易所科创板 成功挂牌上市 股票简称 汉邦科技 股票代码 股票发行价格 22.77元/股 公司主营业务是为制药、生命科学等领域提供专业的分离纯化装备、耗材、应用技术服务及相关的技术解决方案。主要产品是各类小分子药物分离纯化设 备、大分子药物分离纯化设备。 公司长期坚持自主创新。截至招股说明书签署日，公司已获得授权的发明专利共51项，其中境内发明专利38项，海外发明专利13项；曾主持或牵头承担省 级以上科研或产业化项目15项，其中包括国家重大科学仪器设备开发专项项目"超临界流体色谱仪的研制与应用开发"、国家科技型中小企业技术创新基金 项目"药物等制备用模拟移动床色谱分离纯化装置"等国家级项目6项。公司先后获得国家知识产权示范企业、国家专精特新"小巨人"企业等荣誉称号。 公司董事长、法人代表为张大兵，办公地址位于淮安经济技术开发区。 另据"淮安经开区发布"转文报道，在国内色谱分离纯化设备市场，汉邦科技市场份额居行业前列，并致力发展成为全球制药公司整体解决方案的主流提供 商。目前，公司已成为国产药物纯化设备主要厂商之一，国内外超过2 ...

Company Overview - N Hanbang has been listed today with an opening price of 49.00 yuan, representing an increase of 115.20% from its issue price [2] - The company focuses on chromatography technology, integrating research and development, production, and sales, primarily serving the pharmaceutical and life sciences sectors with specialized separation and purification equipment, consumables, application technology services, and related technical solutions [2] Financial Highlights - The total number of shares issued by the company is 22 million, with an online issuance of 7.04 million shares at an issue price of 22.77 yuan per share [2] - The issue price corresponds to a price-to-earnings (P/E) ratio of 26.35, compared to the industry average P/E ratio of 28.04 [2] - The total funds raised from the initial public offering (IPO) amount to 501 million yuan, which will be used for working capital, the construction of a chromatography separation equipment R&D center, and the production projects for laboratory chromatography separation and purification instruments [2] Recent IPO Performance - N Hanbang's first-day performance is notable, with a significant increase of 115.20% [2] - Other recent IPOs on the same day include N Zairun, which saw a rise of 98.12%, and Tian Gong Co., which experienced a dramatic increase of 458.63% [3]

Core Viewpoint - Hanbang Technology has successfully transitioned from a chromatography consumables agent to a leading domestic manufacturer of preparative chromatography equipment, becoming the first stock of chromatography equipment on the Sci-Tech Innovation Board [3][4]. Company Development - Established in 1998, Hanbang Technology initially focused on the agency sales of chromatography consumables, facing market saturation by 2006, which prompted a shift towards independent research and development [4]. - The company launched its first dynamic axial compression column in 2005, and by 2012, revenue from self-developed products surpassed that from agency sales [4][5]. - By 2024, Hanbang Technology was recognized as a "little giant" enterprise by the Ministry of Industry and Information Technology, ranking first in the domestic production-grade small molecule liquid chromatography system market [5]. Talent and R&D - Since 2010, Hanbang Technology has focused on attracting and retaining R&D talent, forming a technical team of 141 members by 2024, including 5 core technical personnel [5]. - The company implements various incentive measures, such as salary bonuses and stock options, to stabilize and develop its core technical team [5]. Market Position and Clientele - Hanbang Technology primarily serves the pharmaceutical industry, with notable clients including domestic giants like Heng Rui Medicine and international pharmaceutical equipment integrators [6][7]. - The company emphasizes the importance of high-purity separation and purification technologies, which are increasingly demanded due to stringent regulatory requirements [7]. Business Model and Solutions - Hanbang Technology adopts a dual approach of product development and customized turnkey services, offering solutions for both small and large molecule drug separation and purification [7]. - The company provides tailored solutions based on client sample characteristics, optimizing chromatography filler performance to reduce production costs [7]. Financial Performance - The company's revenue has shown consistent growth, with figures of 482 million yuan, 619 million yuan, and 691 million yuan from 2022 to 2024, respectively [8]. - Net profit attributable to the parent company has also increased, reaching approximately 79.34 million yuan in 2024 [8]. Future Outlook - Hanbang Technology anticipates continued growth in the domestic liquid chromatography market, with the laboratory liquid chromatography market projected to reach 3.6 billion yuan by 2026 [8]. - The company plans to raise funds through an IPO to enhance production capacity and R&D capabilities, with specific projects aimed at increasing production of chromatography equipment and laboratory instruments [8][9]. - Future technical focuses include optimizing chromatography system pressure resistance, fluid distribution, sealing, and homogenization technologies, as well as developing higher selectivity chromatography materials [9].